RxDoctor Payments Data

Sharon Minott, MD

Pain Medicine · West Bloomfield, MINPI 1811931272

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.1% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations.

$2,969in general payments, 2019–2025

Across 116 payments — averaging $25.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nalu Medical, Inc.$681
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$514
  • Nevro Corp.$327
  • Abbott$287
  • Collegium Pharmaceutical, Inc.$280
  • AbbVie$100
  • plus $780 from 24 others

What the payments were for

  • Travel & lodging$2047%
  • Food & beverage$2,76593%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,969 in reported general payments places this provider in the 55th percentile of 139 pain medicine providers in Michigan.

See all pain medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$87,137
Medicare patients
323
Services billed
1,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl24$19,427
Buprenorphine37$9,572
Fentanyl111$7,621
BelbucaBuprenorphine Hcl12$7,336
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen399$6,727
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen328$5,672
Gabapentin207$2,846
Eszopiclone11$1,097
Oxycodone Hcl54$1,055
Pregabalin59$914
Duloxetine Hcl46$658
Trazodone Hcl61$602
Cyclobenzaprine Hcl79$574
Tizanidine Hcl68$559
Morphine Sulfate ErMorphine Sulfate32$484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$280$7,33612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 139 pain medicine providers in Michigan.

Other pain medicine in West Bloomfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →